Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial.
As Healio previously reported, the SELECT trial randomly assigned 17,604 adults with obesity and established cardiovascular disease to once-weekly semaglutide 2.4 mg (Wegovy, Novo Nordisk) or placebo. In the trial’s primary
Lose to win: British National Health Service offers money to OBESE men to DROP THE POUNDS – NaturalNews com naturalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from naturalnews.com Daily Mail and Mail on Sunday newspapers.
Rapid increase in Type 2 diabetes cases among young Scots heraldscotland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heraldscotland.com Daily Mail and Mail on Sunday newspapers.
Text messages with financial incentives for men with obesity led to nearly two thirds losing 5% body weight over a year, and many men were from socially deprived groups.
New Analysis Confirms Wegovy Can Sustain Weight Loss for 4 Years and Support Heart Health yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.